Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Venetoclax/Rituximab Combo Approved in Europe for CLL

November 1st 2018

The European Commission has approved venetoclax for use in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia following at least 1 prior therapy.

Venetoclax Plus Obinutuzumab Improves PFS in Frontline CLL

November 1st 2018

The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) reduced the risk of disease progression or death versus obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Dr. Hill Discusses the Treatment Landscape of CLL

October 31st 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the treatment landscape of chronic lymphocytic leukemia.

Dr. Kahl on Patient Preference in Treatment Selection for CLL

October 27th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses patient preference in treatment selection for chronic lymphocytic leukemia.

Kahl Highlights Frontline Considerations in Changing CLL Landscape

October 26th 2018

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

CLL Paradigm Rapidly Evolving With Novel Agents

October 25th 2018

Brian T. Hill, MD, PhD, discusses recent advances and regulatory decisions in the treatment of patients with chronic lymphocytic leukemia.

Dr. Kahl on the Impact of Venetoclax in Chronic Lymphocytic Leukemia

October 25th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kahl on Ibrutinib in CLL

October 19th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

FDA Grants Priority Review to Ibrutinib Plus Obinutuzumab in Frontline CLL

October 17th 2018

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Arora Discusses the Role of MRD Status in CLL

October 10th 2018

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of minimal residual disease (MRD) status in the treatment of patients with chronic lymphocytic leukemia.

Combination Trials Signal Next Wave of Treatment for CLL

October 9th 2018

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

Dr. Hill on Recent Advances in Treatment of CLL

October 9th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Novel Agents and Approaches Continue to Advance Through CLL Pipeline

October 7th 2018

Mazyar Shadman, MD, MPH, discusses the evolution of therapy in CLL and how physicians are working to balance novel agents with additional modalities.

BTK Inhibitor Success Puts Focus on Resistance Mechanisms

October 2nd 2018

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.

CLL Landscape Continues to Expand With Addition of Venetoclax

October 1st 2018

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

September 30th 2018

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection

September 29th 2018

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care

September 28th 2018

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Dr. Shadman on the Future of Venetoclax in CLL

September 26th 2018

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Dr. Seymour on Shifting Standards of Care in CLL

September 25th 2018

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).